Home > Insider Trading > Filing (0001209191-19-036426)

Filing Details

Accession Number:: 0001209191-19-036426
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-06-12 17:00:25
Reporting Period:: 2019-06-10

Accepted Time:: 2019-06-12 17:00:25
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1370053	Anaptysbio Inc	ANAB	Pharmaceutical Preparations (2834)	203828755

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1654495	Hamza Suria	C/O Anaptysbio, Inc. 10421 Pacific Center Court, Suite 200 San Diego CA 92121	President, Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2019-06-10	8,540	$72.64	31,524	No	4	S	Direct
Common Stock	Disposition	2019-06-10	6,440	$73.70	25,084	No	4	S	Direct
Common Stock	Disposition	2019-06-10	5,000	$74.68	20,084	No	4	S	Direct
Common Stock	Disposition	2019-06-10	1,994	$75.86	18,090	No	4	S	Direct
Common Stock	Disposition	2019-06-10	454	$76.31	17,636	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.16 to $73.15 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.20 to $74.15 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.20 to $75.12 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.24 to $76.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The Reporting Person also holds options to purchase up to an aggregate of 878,838 shares of common stock, which options vest according to their terms, in addition to the 17,636 shares of common stock held directly as set forth in Table I above.